Bli medlem
Bli medlem

Du är här


Sanofi : Sanofi's CSR Achievements Recognized in the Dow Jones Sustainability Indices

Sanofi's CSR Achievements Recognized in the Dow Jones Sustainability Indices

Paris, France - September 16, 2015
Sanofiannounced today that its Corporate Social Responsibility (CSR)
performance has been recognized in the Dow Jones Sustainability Indices. For
the ninth consecutive year, Sanofi has been included in the DJSI World, the
most recognized international sustainability indices by investors. Sanofi is
also among five pharmaceutical companies selected for the DJSI Europe, a
first in the company's history.

Sanofi improved its ranking in the Dow Jones Sustainability Indices, reaching
the score of 86 out of 100 in 2015, against 83 in 2014. These indices assess
companies' economic, social, societal and environmental performance in 24
distinct areas. Sanofi is recognized as best in class on several criteria
including Strategy to Improve Access to Drugs or Products, Health outcome
contribution, Bioethics, Social Reporting and Stakeholder engagement.

"We are very proud that Sanofi continues to be recognized as one of the most
sustainable companies within the pharmaceutical sector. This success is a
tribute to all our employees and their ongoing commitment to Corporate Social
, said Olivier Brandicourt, MD, Chief Executive Officer, Sanofi.
"Sustainability is an integral part of our corporate strategy and how we do
business every day around the world."

In 2014, Sanofi remained focused on its ambition to protect the health and
respond to the hopes of 7 billion men and women. We continued to include more
beneficiaries in our many access to healthcare programs with more than 89
million patients receiving diagnosis, vaccination, treatment or self-disease
management programs in over 80 countries. As far as environment is concerned,
Sanofi recognized its responsibility to fight against climate change. In
2014, we reduced our environmental impact by decreasing our CO2emissions by
15 percent compared to 2010. Our progress and actions in these various areas
may be viewed on the website:

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths
in diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and Genzyme. Sanofi is listed in Paris
(EURONEXT:SAN) and in New York (NYSE:SNY).

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services, product
development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words "expects",
"anticipates", "believes", "intends", "estimates", "plans" and similar
expressions. Although Sanofi's management believes that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent in
research and development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as
their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence
of guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment policies and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the
year ended December 31, 2014. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.

| Contacts: Investor Relations |
| |
| Sébastien Martel |
|Media Relations Tel.: + (33) 1 53 77 45 45 |
| |
|Laurence Bollack |
|Tel.: + (33) 1 53 77 46 46 |
| |
| |

Press release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.